International treatment guidelines for anaemia in chronic kidney disease - what has changed?: Balancing the risks and benefits of erythropoietin-stimulating agents and iron therapy

Medical Journal of Australia

Volumn 199, Issue 2, 2013, Pages 84-85

  MacGinley, Robert J ^a   Walker, Rowan G ^b  

^a Deakin University Medical School   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AUSTRALIA; BLOOD ANALYSIS; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; EDITORIAL; ERYTHROCYTE TRANSFUSION; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; IRON THERAPY; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; MORTALITY; PATIENT REFERRAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ANEMIA; BLOOD TRANSFUSION; COMBINED MODALITY THERAPY; ERYTHROPOIETIN; HEMATINICS; HUMANS; IRON; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; TRACE ELEMENTS;

EID: 84880649549     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.10538     Document Type: Editorial

References (10)

1. Kidney Health Australia. Key chronic kidney disease (CKD) statistics in Australia. http://www.kidney.org.au/HealthProfessionals/CKDinAustralia/tabid/622/Default.aspx (accessed May 2013).
2. Razavian M, Heeley EL, Perkovic V, et al. Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrol Dial Transplant 2012; 27: 1396-1402.
3. Mercadal L, Metzger M, Casadevall, et al. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: 35-42.
4. Goldsmith D. 2009: A requiem for rHuEPOs - but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 2010; 5: 929-935.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 4: 279-335.
6. MacGinley R, Walker R, Irving M. KHA-CARI Guidelines. Use of iron in chronic kidney disease patients [draft]. August 2012. http://www.cari.org.au/DIALYSIS_bht_published/DRAFT_Iron_18_March_2013.pdf (accessed Apr 2013).
7. McMahon L, MacGinley R. KHA-CARI Guidelines. Biochemical and haematological targets: haemoglobin levels in patients using erythropoiesis stimulating agents. October 2011. http://www.cari.org.au/DIALYSIS_bht_published/KHA_CARI_Anaemia_guidelines_November_%202011.pdf (accessed Apr 2013).
8. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
9. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
10. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesisstimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.